Search
Back to Search

Afrezza

Afrezza from Mannkind

Afrezza (insulin human) Inhalation Powder is the only ultra rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Available by prescription only.

For complete information, visit Mannkind Corporation

  • Inhalables
  • Insulin
  • Product Specifications
  • Rapid-acting
Afrezza insulin inhaler held between an index finger & thumb to show size
Afrezza insulin inhaler with doses of 4, 8 & 12 units

Device Type:

Inhalable Insulin

Reusable Disposable:

Disposable (Single dose only)

Medicine Type:

Afrezza is a ultra rapid-acting inhaled insulin taken at mealtime and helps control postprandial plasma glucose (PPG) in adults with type 1 or type 2 diabetes mellitus.

Insulin Type:

Rapid Acting

Dose Delivery:

Dose is inhaled via single use cartridges.

Largest Dose Possible:

Available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder. For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths.

Total Capacity:

Available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder. For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths.

Memory Function:

No

Audible Click:

Yes

Assistive Dexterity Issue Options:

Yes

Patient Resources

HCP Resources

Training Resources: 

BluHale Pro is an accessory device, designed by MannKind, that mounts onto the inhaler to facilitate healthcare professionals in training patients on proper inhalation technique and handling.*

The BluHale app is designed to be used with the BluHale PRO device by healthcare professionals and is available for Android and IOS devices. 

BluHale Vis is coming soon!

*It is important to keep in mind that BluHale PRO is not a diagnostic device. 

  • Available by prescription, Afrezza® (insulin human) Inhalation Powder is the only available ultra rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.
  • Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler.
  • Afrezza is administered at the beginning of the meal. After inhalation, the insulin passes quickly through the lungs and into the bloodstream (<1 minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within about 12 minutes of administration.
  • Afrezza can cause serious side effects including sudden lung problems (bronchospasms). Patients with long-term (chronic) lung problems such as asthma or chronic obstructive pulmonary disease (COPD) should not use Afrezza. Afrezza is not for use to treat diabetic ketoacidosis.
  • Afrezza is not for use in patients who smoke or have recently stopped smoking (less than 6 months).
  • Afrezza must be used with long-acting insulin in people who have type 1 diabetes. For more information and full Prescribing Information go to www.afrezza.com.

Have a question about this product?
March 2023

The Danatech Digest

Join 25,000+ professionals who get our latest diabetes technology updates

DISCLAIMERS: 

This site and its services do not constitute the practice of medical advice, diagnosis or treatment. Always talk to your diabetes care and education specialist or health care provider for diagnosis and treatment, including your specific medical needs. If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately. To find a diabetes care and education specialist near you, visit the ADCES finder tool.

ADCES and danatech curate product specifics and periodically review them for accuracy and relevance. As a result, the information may or may not be the most recent. We recommend visiting the manufacturer's website for the latest details if you have any questions.

danatech is Made Possible by Grant Funding and Industry Sponsorship